| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthritis, Rheumatoid | 228 | 2024 | 3763 | 27.780 |
Why?
|
| Antirheumatic Agents | 150 | 2024 | 1374 | 24.150 |
Why?
|
| Rheumatology | 44 | 2024 | 611 | 9.730 |
Why?
|
| Osteoporosis | 73 | 2023 | 1600 | 9.460 |
Why?
|
| Gout | 27 | 2024 | 620 | 7.610 |
Why?
|
| Methotrexate | 37 | 2024 | 1719 | 6.970 |
Why?
|
| Bone Density Conservation Agents | 34 | 2023 | 796 | 6.770 |
Why?
|
| Rheumatic Diseases | 31 | 2023 | 639 | 5.110 |
Why?
|
| Diphosphonates | 25 | 2023 | 638 | 5.050 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 51 | 2019 | 2282 | 4.780 |
Why?
|
| Arthritis | 20 | 2024 | 666 | 4.500 |
Why?
|
| Cardiovascular Diseases | 76 | 2024 | 15757 | 3.900 |
Why?
|
| Bone Density | 34 | 2023 | 3534 | 3.790 |
Why?
|
| Fractures, Bone | 31 | 2024 | 2041 | 3.770 |
Why?
|
| Uric Acid | 12 | 2024 | 806 | 3.500 |
Why?
|
| Tumor Necrosis Factor-alpha | 44 | 2023 | 4357 | 3.420 |
Why?
|
| Medication Adherence | 31 | 2023 | 2165 | 3.370 |
Why?
|
| Gout Suppressants | 9 | 2024 | 177 | 3.330 |
Why?
|
| Women's Health | 13 | 2023 | 2056 | 3.100 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 19 | 2017 | 321 | 3.090 |
Why?
|
| Osteoarthritis | 23 | 2022 | 1055 | 2.910 |
Why?
|
| Teriparatide | 5 | 2020 | 227 | 2.810 |
Why?
|
| Biological Products | 21 | 2023 | 916 | 2.720 |
Why?
|
| Registries | 36 | 2023 | 8469 | 2.570 |
Why?
|
| Hydroxychloroquine | 14 | 2024 | 427 | 2.560 |
Why?
|
| Aged | 327 | 2024 | 169152 | 2.480 |
Why?
|
| Middle Aged | 333 | 2024 | 220352 | 2.420 |
Why?
|
| Pharmacoepidemiology | 13 | 2021 | 350 | 2.400 |
Why?
|
| Chondrocalcinosis | 7 | 2024 | 82 | 2.400 |
Why?
|
| Female | 454 | 2024 | 391270 | 2.280 |
Why?
|
| Colchicine | 6 | 2016 | 261 | 2.190 |
Why?
|
| Humans | 659 | 2024 | 760621 | 2.170 |
Why?
|
| Male | 408 | 2024 | 359744 | 2.100 |
Why?
|
| Cohort Studies | 134 | 2024 | 41335 | 2.090 |
Why?
|
| Hyperuricemia | 8 | 2024 | 225 | 2.060 |
Why?
|
| Cyclooxygenase Inhibitors | 14 | 2017 | 364 | 1.990 |
Why?
|
| Arthritis, Psoriatic | 6 | 2019 | 219 | 1.800 |
Why?
|
| Allopurinol | 6 | 2024 | 198 | 1.800 |
Why?
|
| Severity of Illness Index | 54 | 2024 | 15840 | 1.770 |
Why?
|
| Drug Utilization | 11 | 2017 | 1195 | 1.720 |
Why?
|
| Arteritis | 3 | 2024 | 162 | 1.700 |
Why?
|
| Analgesics, Opioid | 17 | 2022 | 3763 | 1.640 |
Why?
|
| Withholding Treatment | 8 | 2023 | 613 | 1.640 |
Why?
|
| Lupus Erythematosus, Systemic | 18 | 2023 | 2159 | 1.600 |
Why?
|
| Hypoglycemic Agents | 10 | 2024 | 3150 | 1.590 |
Why?
|
| Risk Factors | 136 | 2024 | 74359 | 1.590 |
Why?
|
| Pennsylvania | 29 | 2011 | 615 | 1.580 |
Why?
|
| Immunosuppressive Agents | 20 | 2020 | 4166 | 1.560 |
Why?
|
| Spondylarthritis | 6 | 2020 | 58 | 1.440 |
Why?
|
| United States | 153 | 2023 | 72461 | 1.400 |
Why?
|
| Naproxen | 11 | 2019 | 100 | 1.380 |
Why?
|
| Authorship | 2 | 2023 | 281 | 1.380 |
Why?
|
| Medicare | 45 | 2023 | 6786 | 1.350 |
Why?
|
| Longitudinal Studies | 36 | 2024 | 14495 | 1.340 |
Why?
|
| Patient Compliance | 11 | 2021 | 2688 | 1.320 |
Why?
|
| Metformin | 5 | 2024 | 912 | 1.300 |
Why?
|
| Proportional Hazards Models | 50 | 2024 | 12531 | 1.300 |
Why?
|
| Glucocorticoids | 21 | 2024 | 2145 | 1.280 |
Why?
|
| Pain | 18 | 2019 | 5066 | 1.270 |
Why?
|
| Prediabetic State | 2 | 2024 | 550 | 1.260 |
Why?
|
| Antihypertensive Agents | 8 | 2019 | 2061 | 1.250 |
Why?
|
| Aged, 80 and over | 112 | 2024 | 58995 | 1.220 |
Why?
|
| Ibuprofen | 9 | 2019 | 229 | 1.210 |
Why?
|
| Adult | 196 | 2024 | 219994 | 1.210 |
Why?
|
| Patient Education as Topic | 13 | 2011 | 2315 | 1.180 |
Why?
|
| Thiazolidinediones | 5 | 2014 | 465 | 1.180 |
Why?
|
| Publishing | 5 | 2023 | 836 | 1.180 |
Why?
|
| Incidence | 60 | 2024 | 21392 | 1.170 |
Why?
|
| Drug Prescriptions | 18 | 2019 | 1673 | 1.160 |
Why?
|
| Hip Fractures | 10 | 2017 | 989 | 1.160 |
Why?
|
| Psoriasis | 6 | 2017 | 940 | 1.140 |
Why?
|
| Periodicals as Topic | 6 | 2024 | 1469 | 1.140 |
Why?
|
| Diabetes Mellitus | 16 | 2019 | 5889 | 1.120 |
Why?
|
| Lactones | 8 | 2019 | 319 | 1.110 |
Why?
|
| Osteoporotic Fractures | 9 | 2019 | 409 | 1.100 |
Why?
|
| Comorbidity | 34 | 2023 | 10551 | 1.100 |
Why?
|
| Antibodies, Monoclonal | 17 | 2018 | 9185 | 1.090 |
Why?
|
| Nurse Practitioners | 3 | 2015 | 268 | 1.080 |
Why?
|
| Hand Joints | 3 | 2023 | 58 | 1.080 |
Why?
|
| Databases, Factual | 35 | 2024 | 8035 | 1.070 |
Why?
|
| Osteoarthritis, Knee | 19 | 2020 | 1234 | 1.060 |
Why?
|
| Myocardial Infarction | 36 | 2022 | 11891 | 1.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 18 | 2023 | 3334 | 1.020 |
Why?
|
| Osteoporosis, Postmenopausal | 6 | 2011 | 393 | 1.020 |
Why?
|
| Arthralgia | 4 | 2020 | 461 | 1.010 |
Why?
|
| Editorial Policies | 3 | 2021 | 457 | 1.000 |
Why?
|
| Treatment Outcome | 81 | 2024 | 65017 | 0.980 |
Why?
|
| Uterine Cervical Dysplasia | 4 | 2016 | 384 | 0.960 |
Why?
|
| Prescription Drugs | 6 | 2021 | 630 | 0.950 |
Why?
|
| Remission Induction | 14 | 2024 | 2392 | 0.940 |
Why?
|
| C-Reactive Protein | 16 | 2024 | 3839 | 0.900 |
Why?
|
| Absorptiometry, Photon | 7 | 2019 | 1736 | 0.890 |
Why?
|
| Risk Assessment | 30 | 2020 | 24123 | 0.890 |
Why?
|
| Drug Substitution | 5 | 2021 | 296 | 0.890 |
Why?
|
| Artificial Intelligence | 3 | 2023 | 2557 | 0.880 |
Why?
|
| Pain Measurement | 15 | 2019 | 3528 | 0.880 |
Why?
|
| Sulfasalazine | 5 | 2024 | 84 | 0.870 |
Why?
|
| Time Factors | 48 | 2024 | 40165 | 0.860 |
Why?
|
| Comparative Effectiveness Research | 8 | 2020 | 718 | 0.860 |
Why?
|
| Insurance, Pharmaceutical Services | 5 | 2011 | 345 | 0.860 |
Why?
|
| Propensity Score | 16 | 2024 | 1928 | 0.840 |
Why?
|
| Patient Care Planning | 3 | 2019 | 908 | 0.830 |
Why?
|
| Office Visits | 5 | 2024 | 597 | 0.830 |
Why?
|
| Metacarpophalangeal Joint | 2 | 2020 | 82 | 0.830 |
Why?
|
| Drug Therapy, Combination | 15 | 2024 | 6498 | 0.830 |
Why?
|
| Physician Assistants | 2 | 2015 | 188 | 0.830 |
Why?
|
| Lipids | 7 | 2024 | 3336 | 0.800 |
Why?
|
| Randomized Controlled Trials as Topic | 17 | 2020 | 10344 | 0.790 |
Why?
|
| Quality Improvement | 9 | 2021 | 3836 | 0.780 |
Why?
|
| Opportunistic Infections | 5 | 2019 | 377 | 0.780 |
Why?
|
| Spondylitis, Ankylosing | 2 | 2020 | 152 | 0.770 |
Why?
|
| Polyglutamic Acid | 1 | 2021 | 44 | 0.770 |
Why?
|
| Research Design | 19 | 2022 | 6180 | 0.770 |
Why?
|
| Sulfones | 8 | 2019 | 447 | 0.770 |
Why?
|
| Education, Distance | 2 | 2022 | 258 | 0.760 |
Why?
|
| Insurance Claim Review | 8 | 2020 | 738 | 0.760 |
Why?
|
| Uterine Cervical Neoplasms | 6 | 2016 | 2003 | 0.760 |
Why?
|
| Diabetes Mellitus, Type 2 | 9 | 2023 | 12293 | 0.750 |
Why?
|
| Femur Neck | 7 | 2019 | 312 | 0.750 |
Why?
|
| Antidepressive Agents | 7 | 2019 | 2890 | 0.750 |
Why?
|
| Drug Utilization Review | 7 | 2014 | 251 | 0.740 |
Why?
|
| Education, Medical, Continuing | 5 | 2009 | 830 | 0.740 |
Why?
|
| Finger Joint | 2 | 2023 | 108 | 0.740 |
Why?
|
| Disease Management | 6 | 2018 | 2514 | 0.730 |
Why?
|
| Age Factors | 36 | 2020 | 18416 | 0.730 |
Why?
|
| Drug Administration Schedule | 12 | 2020 | 4899 | 0.730 |
Why?
|
| Retrospective Studies | 73 | 2024 | 80372 | 0.720 |
Why?
|
| Data Display | 1 | 2021 | 174 | 0.720 |
Why?
|
| Arthroplasty, Replacement, Knee | 12 | 2022 | 1370 | 0.710 |
Why?
|
| Gastrointestinal Diseases | 9 | 2018 | 1190 | 0.710 |
Why?
|
| Medical Records | 12 | 2010 | 1407 | 0.710 |
Why?
|
| Patient Participation | 4 | 2021 | 1439 | 0.710 |
Why?
|
| Rheumatoid Factor | 6 | 2014 | 185 | 0.710 |
Why?
|
| Quality Indicators, Health Care | 7 | 2021 | 1824 | 0.690 |
Why?
|
| Probenecid | 2 | 2018 | 73 | 0.690 |
Why?
|
| Plagiarism | 1 | 2019 | 22 | 0.680 |
Why?
|
| Oral Ulcer | 1 | 2020 | 96 | 0.680 |
Why?
|
| Medicaid | 15 | 2019 | 2815 | 0.670 |
Why?
|
| Electronic Health Records | 9 | 2024 | 4775 | 0.670 |
Why?
|
| Leukopenia | 1 | 2020 | 211 | 0.670 |
Why?
|
| Hospitalization | 31 | 2019 | 10790 | 0.670 |
Why?
|
| Double-Blind Method | 16 | 2021 | 12427 | 0.670 |
Why?
|
| Kidney Diseases | 6 | 2018 | 2093 | 0.660 |
Why?
|
| Serologic Tests | 2 | 2017 | 383 | 0.660 |
Why?
|
| Depressive Disorder | 4 | 2019 | 3726 | 0.650 |
Why?
|
| Quality Assurance, Health Care | 9 | 2013 | 2176 | 0.650 |
Why?
|
| Professional Practice | 4 | 2019 | 313 | 0.650 |
Why?
|
| Hyperlipidemias | 8 | 2018 | 782 | 0.650 |
Why?
|
| Follow-Up Studies | 37 | 2024 | 39261 | 0.640 |
Why?
|
| Quality of Health Care | 13 | 2015 | 4360 | 0.640 |
Why?
|
| Telemedicine | 5 | 2024 | 3018 | 0.630 |
Why?
|
| Calcium Pyrophosphate | 4 | 2024 | 53 | 0.630 |
Why?
|
| New Jersey | 9 | 2011 | 291 | 0.620 |
Why?
|
| Telephone | 4 | 2022 | 624 | 0.620 |
Why?
|
| Nursing Homes | 8 | 2012 | 1082 | 0.620 |
Why?
|
| Hypertension | 17 | 2023 | 8594 | 0.610 |
Why?
|
| Biomedical Technology | 1 | 2020 | 211 | 0.600 |
Why?
|
| Risk | 25 | 2020 | 9631 | 0.600 |
Why?
|
| Ethics, Research | 1 | 2019 | 176 | 0.600 |
Why?
|
| Patient Care Management | 1 | 2021 | 303 | 0.600 |
Why?
|
| Orphan Drug Production | 3 | 2019 | 48 | 0.600 |
Why?
|
| Prescriptions | 2 | 2021 | 388 | 0.600 |
Why?
|
| Jaw Diseases | 2 | 2009 | 92 | 0.590 |
Why?
|
| Patient Satisfaction | 10 | 2021 | 3448 | 0.590 |
Why?
|
| Stomatitis | 1 | 2020 | 271 | 0.590 |
Why?
|
| Chronic Disease | 11 | 2019 | 9287 | 0.580 |
Why?
|
| Logistic Models | 22 | 2019 | 13314 | 0.580 |
Why?
|
| Trust | 3 | 2019 | 532 | 0.580 |
Why?
|
| Health Care Costs | 12 | 2018 | 3258 | 0.580 |
Why?
|
| Focus Groups | 4 | 2020 | 1378 | 0.570 |
Why?
|
| Self Care | 5 | 2013 | 793 | 0.570 |
Why?
|
| Bone Diseases | 2 | 2012 | 419 | 0.570 |
Why?
|
| Algorithms | 19 | 2023 | 13981 | 0.570 |
Why?
|
| Sex Factors | 16 | 2020 | 10547 | 0.570 |
Why?
|
| Linear Models | 13 | 2020 | 5877 | 0.560 |
Why?
|
| Health Services Accessibility | 7 | 2019 | 5397 | 0.560 |
Why?
|
| Medical Records Systems, Computerized | 5 | 2017 | 1191 | 0.550 |
Why?
|
| Health Resources | 4 | 2019 | 935 | 0.550 |
Why?
|
| Biological Factors | 2 | 2015 | 157 | 0.550 |
Why?
|
| Neutropenia | 2 | 2020 | 884 | 0.550 |
Why?
|
| Managed Care Programs | 4 | 2016 | 939 | 0.540 |
Why?
|
| Autoimmune Diseases | 10 | 2024 | 2250 | 0.540 |
Why?
|
| Guideline Adherence | 7 | 2018 | 2283 | 0.540 |
Why?
|
| International Classification of Diseases | 7 | 2020 | 894 | 0.540 |
Why?
|
| Stroke | 18 | 2022 | 9962 | 0.530 |
Why?
|
| Hand Bones | 1 | 2016 | 13 | 0.530 |
Why?
|
| Physicians, Family | 5 | 2009 | 349 | 0.530 |
Why?
|
| Health Behavior | 5 | 2016 | 2622 | 0.530 |
Why?
|
| Neoplasms | 19 | 2022 | 22072 | 0.530 |
Why?
|
| Receptors, Tumor Necrosis Factor | 6 | 2012 | 585 | 0.530 |
Why?
|
| Models, Economic | 6 | 2015 | 719 | 0.530 |
Why?
|
| Health Status | 6 | 2023 | 4081 | 0.520 |
Why?
|
| Alopecia | 1 | 2020 | 414 | 0.520 |
Why?
|
| Osteitis Deformans | 1 | 2015 | 54 | 0.520 |
Why?
|
| Insurance Claim Reporting | 3 | 2007 | 165 | 0.520 |
Why?
|
| Bone Diseases, Metabolic | 2 | 2017 | 409 | 0.520 |
Why?
|
| Health Knowledge, Attitudes, Practice | 6 | 2014 | 3986 | 0.510 |
Why?
|
| Drug Approval | 4 | 2016 | 816 | 0.510 |
Why?
|
| Knee Injuries | 7 | 2014 | 489 | 0.510 |
Why?
|
| Coronary Vessels | 3 | 2024 | 3112 | 0.500 |
Why?
|
| Fractures, Ununited | 2 | 2008 | 172 | 0.500 |
Why?
|
| Peptic Ulcer | 3 | 2009 | 219 | 0.500 |
Why?
|
| Aspirin | 8 | 2018 | 3364 | 0.490 |
Why?
|
| Immunocompromised Host | 5 | 2017 | 857 | 0.490 |
Why?
|
| Menstruation | 1 | 2016 | 307 | 0.490 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2021 | 3164 | 0.490 |
Why?
|
| Xanthine Oxidase | 1 | 2015 | 69 | 0.490 |
Why?
|
| Fibromyalgia | 7 | 2022 | 401 | 0.490 |
Why?
|
| Specialization | 6 | 2015 | 778 | 0.480 |
Why?
|
| Gastrointestinal Hemorrhage | 5 | 2017 | 1131 | 0.480 |
Why?
|
| Interleukin-1beta | 3 | 2024 | 998 | 0.480 |
Why?
|
| Seafood | 1 | 2018 | 390 | 0.480 |
Why?
|
| Odds Ratio | 16 | 2020 | 9716 | 0.470 |
Why?
|
| Patient Selection | 6 | 2017 | 4283 | 0.470 |
Why?
|
| Physicians' Offices | 1 | 2014 | 60 | 0.470 |
Why?
|
| Antibodies, Antinuclear | 5 | 2024 | 344 | 0.470 |
Why?
|
| Alcohol Drinking | 4 | 2024 | 4013 | 0.470 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2017 | 370 | 0.470 |
Why?
|
| Conflict of Interest | 1 | 2019 | 549 | 0.470 |
Why?
|
| Dengue | 1 | 2017 | 254 | 0.470 |
Why?
|
| Databases as Topic | 3 | 2011 | 474 | 0.470 |
Why?
|
| Cyclopropanes | 1 | 2015 | 431 | 0.460 |
Why?
|
| Liver Cirrhosis | 4 | 2024 | 1931 | 0.460 |
Why?
|
| Hepatitis B virus | 1 | 2017 | 522 | 0.460 |
Why?
|
| Antidepressive Agents, Tricyclic | 2 | 2013 | 432 | 0.460 |
Why?
|
| Familial Mediterranean Fever | 2 | 2015 | 65 | 0.460 |
Why?
|
| Primary Prevention | 2 | 2019 | 1207 | 0.460 |
Why?
|
| Coronary Circulation | 2 | 2024 | 1577 | 0.450 |
Why?
|
| Arthrography | 2 | 2011 | 149 | 0.450 |
Why?
|
| Humeral Fractures | 2 | 2008 | 282 | 0.450 |
Why?
|
| Multivariate Analysis | 21 | 2019 | 12159 | 0.450 |
Why?
|
| Inflammation | 16 | 2024 | 10756 | 0.450 |
Why?
|
| Immunoglobulin G | 13 | 2023 | 4541 | 0.450 |
Why?
|
| Epidemiologic Methods | 9 | 2017 | 1343 | 0.450 |
Why?
|
| Myocardial Perfusion Imaging | 2 | 2024 | 571 | 0.450 |
Why?
|
| Hepatitis B, Chronic | 1 | 2018 | 403 | 0.450 |
Why?
|
| United States Food and Drug Administration | 6 | 2016 | 1677 | 0.450 |
Why?
|
| Histamine H2 Antagonists | 1 | 2015 | 167 | 0.440 |
Why?
|
| Data Mining | 2 | 2021 | 553 | 0.440 |
Why?
|
| Dose-Response Relationship, Drug | 18 | 2021 | 10827 | 0.440 |
Why?
|
| Osteonecrosis | 3 | 2012 | 229 | 0.440 |
Why?
|
| Sex Distribution | 11 | 2017 | 2295 | 0.440 |
Why?
|
| Amitriptyline | 1 | 2013 | 112 | 0.440 |
Why?
|
| Kaplan-Meier Estimate | 10 | 2017 | 6544 | 0.440 |
Why?
|
| Coronary Artery Disease | 9 | 2024 | 6659 | 0.440 |
Why?
|
| Prunus | 1 | 2012 | 10 | 0.430 |
Why?
|
| Speech Recognition Software | 2 | 2020 | 74 | 0.430 |
Why?
|
| Immunologic Factors | 6 | 2022 | 1588 | 0.430 |
Why?
|
| Folic Acid | 4 | 2021 | 1309 | 0.430 |
Why?
|
| Age Distribution | 10 | 2017 | 2893 | 0.430 |
Why?
|
| Osteoarthritis, Hip | 4 | 2020 | 406 | 0.420 |
Why?
|
| Atrial Fibrillation | 7 | 2019 | 5209 | 0.420 |
Why?
|
| Sulfonamides | 7 | 2015 | 1977 | 0.420 |
Why?
|
| Nurse's Role | 1 | 2014 | 188 | 0.420 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2013 | 140 | 0.420 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2014 | 298 | 0.420 |
Why?
|
| Hypericum | 1 | 2013 | 58 | 0.420 |
Why?
|
| Insect Hormones | 1 | 2012 | 73 | 0.420 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2017 | 611 | 0.420 |
Why?
|
| Pyrrolidonecarboxylic Acid | 1 | 2012 | 65 | 0.420 |
Why?
|
| Insulin | 3 | 2017 | 6597 | 0.420 |
Why?
|
| Proton Pump Inhibitors | 3 | 2015 | 551 | 0.420 |
Why?
|
| Physician Executives | 1 | 2013 | 133 | 0.410 |
Why?
|
| Cost-Benefit Analysis | 13 | 2016 | 5508 | 0.410 |
Why?
|
| Inflammatory Bowel Diseases | 3 | 2017 | 2421 | 0.410 |
Why?
|
| Insurance, Health | 7 | 2017 | 2501 | 0.410 |
Why?
|
| Insulin Resistance | 4 | 2014 | 3959 | 0.400 |
Why?
|
| Research | 2 | 2020 | 1974 | 0.400 |
Why?
|
| Plant Preparations | 1 | 2013 | 94 | 0.400 |
Why?
|
| Anemia | 2 | 2020 | 1511 | 0.400 |
Why?
|
| Case-Control Studies | 19 | 2024 | 22053 | 0.400 |
Why?
|
| Hepatitis B | 1 | 2017 | 701 | 0.400 |
Why?
|
| Adrenal Cortex Hormones | 5 | 2015 | 1869 | 0.400 |
Why?
|
| Thrombocytopenia | 1 | 2020 | 1174 | 0.400 |
Why?
|
| Spinal Fractures | 3 | 2009 | 702 | 0.400 |
Why?
|
| Amines | 1 | 2013 | 281 | 0.400 |
Why?
|
| Pneumococcal Vaccines | 2 | 2013 | 397 | 0.390 |
Why?
|
| Monitoring, Physiologic | 1 | 2019 | 1784 | 0.380 |
Why?
|
| Prospective Studies | 31 | 2020 | 54303 | 0.380 |
Why?
|
| Bacterial Infections | 4 | 2019 | 1403 | 0.380 |
Why?
|
| Etidronic Acid | 4 | 2009 | 63 | 0.380 |
Why?
|
| Esophageal Neoplasms | 3 | 2011 | 1648 | 0.380 |
Why?
|
| Diaphyses | 1 | 2011 | 65 | 0.380 |
Why?
|
| Mass Screening | 7 | 2018 | 5423 | 0.370 |
Why?
|
| Femoral Fractures | 2 | 2013 | 375 | 0.370 |
Why?
|
| Pneumococcal Infections | 2 | 2013 | 503 | 0.370 |
Why?
|
| Phytotherapy | 1 | 2013 | 295 | 0.360 |
Why?
|
| Narcotics | 3 | 2011 | 336 | 0.360 |
Why?
|
| Interleukin-1 | 1 | 2014 | 1249 | 0.360 |
Why?
|
| Hand | 3 | 2012 | 903 | 0.360 |
Why?
|
| Pharmacy | 2 | 2022 | 92 | 0.350 |
Why?
|
| Prednisone | 5 | 2015 | 1565 | 0.350 |
Why?
|
| Decision Making | 7 | 2018 | 3925 | 0.350 |
Why?
|
| Confidence Intervals | 10 | 2018 | 2932 | 0.350 |
Why?
|
| Administration, Oral | 10 | 2018 | 4035 | 0.350 |
Why?
|
| Analgesics | 4 | 2017 | 1065 | 0.350 |
Why?
|
| Information Services | 1 | 2011 | 235 | 0.350 |
Why?
|
| Vasodilation | 1 | 2014 | 962 | 0.350 |
Why?
|
| Predictive Value of Tests | 20 | 2017 | 15289 | 0.350 |
Why?
|
| Access to Information | 2 | 2023 | 320 | 0.350 |
Why?
|
| Community Health Centers | 1 | 2013 | 453 | 0.340 |
Why?
|
| Safety-Based Drug Withdrawals | 1 | 2009 | 36 | 0.340 |
Why?
|
| Practice Guidelines as Topic | 12 | 2020 | 7475 | 0.340 |
Why?
|
| PPAR gamma | 1 | 2013 | 484 | 0.340 |
Why?
|
| Population Surveillance | 1 | 2020 | 2608 | 0.340 |
Why?
|
| United States Department of Veterans Affairs | 3 | 2011 | 919 | 0.340 |
Why?
|
| Calcitonin | 5 | 2010 | 330 | 0.340 |
Why?
|
| Physicians | 5 | 2015 | 4591 | 0.340 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2014 | 334 | 0.340 |
Why?
|
| General Practitioners | 1 | 2011 | 102 | 0.340 |
Why?
|
| Data Collection | 8 | 2013 | 3315 | 0.340 |
Why?
|
| Motivation | 2 | 2010 | 1993 | 0.340 |
Why?
|
| Glomerular Filtration Rate | 5 | 2024 | 2180 | 0.330 |
Why?
|
| Automobile Driving | 1 | 2014 | 438 | 0.330 |
Why?
|
| Academic Medical Centers | 7 | 2019 | 2754 | 0.330 |
Why?
|
| Thiophenes | 1 | 2013 | 587 | 0.330 |
Why?
|
| Angina, Unstable | 3 | 2003 | 926 | 0.320 |
Why?
|
| Metacarpal Bones | 1 | 2009 | 75 | 0.320 |
Why?
|
| Prevalence | 19 | 2020 | 15687 | 0.320 |
Why?
|
| Angioplasty, Balloon, Coronary | 2 | 2010 | 1880 | 0.320 |
Why?
|
| Patents as Topic | 1 | 2010 | 112 | 0.320 |
Why?
|
| Pneumonia | 2 | 2020 | 2131 | 0.320 |
Why?
|
| Lumbar Vertebrae | 5 | 2017 | 1868 | 0.320 |
Why?
|
| Knee Joint | 6 | 2020 | 1663 | 0.320 |
Why?
|
| Delphi Technique | 2 | 2019 | 829 | 0.320 |
Why?
|
| Delivery of Health Care | 4 | 2014 | 5325 | 0.310 |
Why?
|
| Decision Support Techniques | 3 | 2010 | 2001 | 0.310 |
Why?
|
| Referral and Consultation | 8 | 2022 | 3598 | 0.310 |
Why?
|
| Histamine Antagonists | 1 | 2008 | 90 | 0.310 |
Why?
|
| Smoking | 9 | 2023 | 9073 | 0.310 |
Why?
|
| Alendronate | 3 | 2009 | 173 | 0.310 |
Why?
|
| Fractures, Spontaneous | 3 | 2005 | 231 | 0.310 |
Why?
|
| Azathioprine | 3 | 2019 | 356 | 0.310 |
Why?
|
| Arthroplasty, Replacement, Hip | 5 | 2020 | 1406 | 0.310 |
Why?
|
| Leucovorin | 2 | 2020 | 641 | 0.310 |
Why?
|
| Regression Analysis | 9 | 2023 | 6360 | 0.310 |
Why?
|
| Lupus Nephritis | 4 | 2013 | 318 | 0.310 |
Why?
|
| Quality-Adjusted Life Years | 6 | 2015 | 1724 | 0.300 |
Why?
|
| Venous Thromboembolism | 3 | 2021 | 1864 | 0.300 |
Why?
|
| Graves Disease | 21 | 1985 | 239 | 0.300 |
Why?
|
| Quality of Life | 9 | 2019 | 13308 | 0.300 |
Why?
|
| Chi-Square Distribution | 6 | 2019 | 3465 | 0.300 |
Why?
|
| Diagnosis-Related Groups | 3 | 2011 | 450 | 0.300 |
Why?
|
| Evidence-Based Medicine | 9 | 2013 | 3696 | 0.290 |
Why?
|
| Health Care Surveys | 3 | 2014 | 2435 | 0.290 |
Why?
|
| Models, Statistical | 11 | 2022 | 5075 | 0.290 |
Why?
|
| Health Surveys | 7 | 2017 | 4063 | 0.290 |
Why?
|
| Medicare Part B | 2 | 2012 | 117 | 0.290 |
Why?
|
| Japan | 3 | 2024 | 1369 | 0.290 |
Why?
|
| Germ-Line Mutation | 1 | 2015 | 1841 | 0.290 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2021 | 2290 | 0.290 |
Why?
|
| British Columbia | 6 | 2012 | 240 | 0.290 |
Why?
|
| Heart Failure | 7 | 2022 | 11847 | 0.290 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2013 | 1132 | 0.290 |
Why?
|
| Attitude to Health | 1 | 2016 | 2029 | 0.290 |
Why?
|
| Health Policy | 3 | 2011 | 2677 | 0.280 |
Why?
|
| Radiography | 8 | 2023 | 6965 | 0.280 |
Why?
|
| Jaw | 1 | 2007 | 93 | 0.280 |
Why?
|
| Database Management Systems | 1 | 2008 | 258 | 0.280 |
Why?
|
| Triiodothyronine | 25 | 1993 | 493 | 0.280 |
Why?
|
| Oligopeptides | 1 | 2012 | 1187 | 0.280 |
Why?
|
| Autoantibodies | 10 | 2024 | 2118 | 0.280 |
Why?
|
| United States Agency for Healthcare Research and Quality | 1 | 2007 | 87 | 0.280 |
Why?
|
| Licensure, Medical | 1 | 2007 | 68 | 0.280 |
Why?
|
| Physical Examination | 3 | 2004 | 1244 | 0.280 |
Why?
|
| Educational Status | 3 | 2023 | 2515 | 0.270 |
Why?
|
| Vertebroplasty | 1 | 2007 | 78 | 0.270 |
Why?
|
| Inflammation Mediators | 4 | 2024 | 1881 | 0.270 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2011 | 936 | 0.270 |
Why?
|
| Cross-Sectional Studies | 17 | 2022 | 25942 | 0.270 |
Why?
|
| Body Mass Index | 11 | 2022 | 12914 | 0.270 |
Why?
|
| Exercise | 1 | 2023 | 5787 | 0.270 |
Why?
|
| Interviews as Topic | 3 | 2014 | 2659 | 0.270 |
Why?
|
| Physicians, Primary Care | 2 | 2019 | 624 | 0.270 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 2 | 2012 | 488 | 0.270 |
Why?
|
| Hip Joint | 4 | 2017 | 1006 | 0.270 |
Why?
|
| Patient Care | 2 | 2014 | 624 | 0.260 |
Why?
|
| Mycophenolic Acid | 2 | 2019 | 343 | 0.260 |
Why?
|
| Prognosis | 16 | 2022 | 29658 | 0.260 |
Why?
|
| Disability Evaluation | 5 | 2023 | 1826 | 0.260 |
Why?
|
| Lipoproteins, HDL | 2 | 2012 | 667 | 0.260 |
Why?
|
| Reproducibility of Results | 14 | 2021 | 20080 | 0.260 |
Why?
|
| Pharmaceutical Services | 2 | 2018 | 141 | 0.260 |
Why?
|
| Eating | 1 | 2012 | 1539 | 0.260 |
Why?
|
| Insurance Benefits | 2 | 2019 | 191 | 0.260 |
Why?
|
| Sensitivity and Specificity | 20 | 2020 | 14660 | 0.260 |
Why?
|
| Menisci, Tibial | 3 | 2020 | 269 | 0.260 |
Why?
|
| Healthcare Disparities | 4 | 2017 | 3388 | 0.260 |
Why?
|
| Low Back Pain | 2 | 2022 | 979 | 0.250 |
Why?
|
| Tramadol | 3 | 2016 | 60 | 0.250 |
Why?
|
| Documentation | 3 | 2007 | 893 | 0.250 |
Why?
|
| Feeding Behavior | 1 | 2017 | 3185 | 0.250 |
Why?
|
| Virus Diseases | 2 | 2019 | 720 | 0.250 |
Why?
|
| Public Opinion | 2 | 2006 | 481 | 0.250 |
Why?
|
| Immunologic Tests | 2 | 2003 | 103 | 0.250 |
Why?
|
| Positron-Emission Tomography | 3 | 2024 | 6465 | 0.250 |
Why?
|
| Drug and Narcotic Control | 1 | 2006 | 145 | 0.250 |
Why?
|
| Morbidity | 4 | 2020 | 1765 | 0.250 |
Why?
|
| Isoenzymes | 3 | 2004 | 1690 | 0.250 |
Why?
|
| Recurrence | 5 | 2019 | 8482 | 0.240 |
Why?
|
| Teaching Materials | 1 | 2005 | 84 | 0.240 |
Why?
|
| Pharmacies | 2 | 2021 | 164 | 0.240 |
Why?
|
| Hypolipidemic Agents | 6 | 2018 | 626 | 0.240 |
Why?
|
| Disease Progression | 12 | 2019 | 13502 | 0.240 |
Why?
|
| Shoulder Pain | 3 | 2001 | 148 | 0.230 |
Why?
|
| Peer Review, Research | 2 | 2019 | 340 | 0.230 |
Why?
|
| Musculoskeletal Diseases | 3 | 2001 | 595 | 0.230 |
Why?
|
| Necrosis | 2 | 2022 | 1612 | 0.230 |
Why?
|
| Beer | 1 | 2024 | 134 | 0.230 |
Why?
|
| Point-of-Care Systems | 1 | 2013 | 1204 | 0.230 |
Why?
|
| Massachusetts | 6 | 2020 | 8803 | 0.230 |
Why?
|
| Primary Health Care | 5 | 2016 | 4647 | 0.220 |
Why?
|
| Cross-Over Studies | 4 | 2015 | 2061 | 0.220 |
Why?
|
| Epidemiologic Studies | 2 | 2006 | 670 | 0.220 |
Why?
|
| Natural Language Processing | 3 | 2023 | 1135 | 0.220 |
Why?
|
| Diet Surveys | 2 | 2018 | 1161 | 0.220 |
Why?
|
| Cluster Analysis | 6 | 2020 | 2698 | 0.220 |
Why?
|
| Joint Diseases | 3 | 2004 | 457 | 0.220 |
Why?
|
| Diabetes Complications | 2 | 2008 | 1341 | 0.220 |
Why?
|
| Tuberculosis, Osteoarticular | 1 | 2003 | 26 | 0.220 |
Why?
|
| Medication Systems, Hospital | 2 | 2020 | 154 | 0.220 |
Why?
|
| Coronary Disease | 4 | 2019 | 5990 | 0.220 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 2 | 2021 | 67 | 0.210 |
Why?
|
| Nutrition Surveys | 3 | 2018 | 1725 | 0.210 |
Why?
|
| Adolescent | 35 | 2024 | 87810 | 0.210 |
Why?
|
| Vasculitis | 2 | 2024 | 523 | 0.210 |
Why?
|
| Family Practice | 2 | 2003 | 510 | 0.210 |
Why?
|
| Poverty | 3 | 2014 | 2695 | 0.210 |
Why?
|
| Oxycodone | 2 | 2016 | 138 | 0.210 |
Why?
|
| Obesity | 7 | 2017 | 12922 | 0.210 |
Why?
|
| Drug Costs | 6 | 2015 | 1185 | 0.210 |
Why?
|
| Cost of Illness | 4 | 2019 | 1940 | 0.200 |
Why?
|
| Data Interpretation, Statistical | 7 | 2018 | 2696 | 0.200 |
Why?
|
| Coronary Artery Bypass | 5 | 2015 | 2272 | 0.200 |
Why?
|
| Patient Dropouts | 1 | 2024 | 412 | 0.200 |
Why?
|
| Preventive Health Services | 1 | 2007 | 570 | 0.200 |
Why?
|
| Cholesterol, LDL | 3 | 2016 | 2420 | 0.200 |
Why?
|
| Blood Pressure | 5 | 2019 | 8525 | 0.200 |
Why?
|
| Science | 1 | 2005 | 239 | 0.200 |
Why?
|
| Program Development | 1 | 2008 | 1297 | 0.200 |
Why?
|
| Drug Discovery | 1 | 2010 | 1057 | 0.200 |
Why?
|
| Hormone Replacement Therapy | 2 | 2015 | 755 | 0.200 |
Why?
|
| International Cooperation | 1 | 2008 | 1433 | 0.200 |
Why?
|
| Heart Diseases | 2 | 2015 | 2809 | 0.200 |
Why?
|
| Accidental Falls | 3 | 2019 | 1056 | 0.190 |
Why?
|
| Socioeconomic Factors | 7 | 2019 | 7806 | 0.190 |
Why?
|
| Thyroxine | 25 | 1993 | 667 | 0.190 |
Why?
|
| Motor Activity | 2 | 2015 | 2687 | 0.190 |
Why?
|
| Knee | 1 | 2003 | 276 | 0.190 |
Why?
|
| Thoracic Vertebrae | 1 | 2006 | 597 | 0.190 |
Why?
|
| Pain Threshold | 3 | 2015 | 603 | 0.190 |
Why?
|
| Fluorobenzenes | 2 | 2015 | 180 | 0.190 |
Why?
|
| Young Adult | 24 | 2024 | 58741 | 0.180 |
Why?
|
| Long-Acting Thyroid Stimulator | 13 | 1979 | 13 | 0.180 |
Why?
|
| Suicide | 2 | 2010 | 1599 | 0.180 |
Why?
|
| Reimbursement Mechanisms | 1 | 2006 | 664 | 0.180 |
Why?
|
| Colonic Neoplasms | 1 | 2012 | 2526 | 0.180 |
Why?
|
| Postmenopause | 4 | 2016 | 2509 | 0.180 |
Why?
|
| Menopause | 3 | 2019 | 1640 | 0.180 |
Why?
|
| Sulfonylurea Compounds | 2 | 2014 | 221 | 0.180 |
Why?
|
| Physician-Patient Relations | 7 | 2021 | 3242 | 0.170 |
Why?
|
| Acute Disease | 7 | 2024 | 7269 | 0.170 |
Why?
|
| Triangular Fibrocartilage | 1 | 2020 | 27 | 0.170 |
Why?
|
| Self Efficacy | 3 | 2011 | 630 | 0.170 |
Why?
|
| Cholesterol | 2 | 2007 | 2924 | 0.170 |
Why?
|
| Thyronines | 7 | 1988 | 7 | 0.170 |
Why?
|
| Taiwan | 2 | 2017 | 505 | 0.170 |
Why?
|
| Treatment Failure | 4 | 2013 | 2648 | 0.170 |
Why?
|
| Diagnostic Tests, Routine | 3 | 2012 | 786 | 0.170 |
Why?
|
| User-Computer Interface | 1 | 2006 | 1403 | 0.170 |
Why?
|
| Thyroid Gland | 21 | 1979 | 1168 | 0.170 |
Why?
|
| Benzodiazepines | 1 | 2005 | 1131 | 0.170 |
Why?
|
| Diet | 1 | 2017 | 8010 | 0.170 |
Why?
|
| Patients | 1 | 2006 | 906 | 0.170 |
Why?
|
| Computer Simulation | 8 | 2019 | 6218 | 0.170 |
Why?
|
| Knee Prosthesis | 2 | 2013 | 394 | 0.170 |
Why?
|
| Perimenopause | 1 | 2020 | 141 | 0.160 |
Why?
|
| Nurses | 3 | 2014 | 2467 | 0.160 |
Why?
|
| Terminology as Topic | 4 | 2013 | 1535 | 0.160 |
Why?
|
| Microcirculation | 1 | 2024 | 1278 | 0.160 |
Why?
|
| Pancytopenia | 1 | 2020 | 101 | 0.160 |
Why?
|
| Treatment Refusal | 3 | 2007 | 430 | 0.160 |
Why?
|
| Ligaments, Articular | 1 | 2001 | 300 | 0.160 |
Why?
|
| Osteomyelitis | 1 | 2003 | 407 | 0.160 |
Why?
|
| Interleukin-18 | 1 | 2020 | 251 | 0.160 |
Why?
|
| Adrenergic beta-Antagonists | 3 | 2015 | 1259 | 0.160 |
Why?
|
| Cardiotonic Agents | 1 | 2002 | 546 | 0.160 |
Why?
|
| Self Report | 6 | 2020 | 3711 | 0.160 |
Why?
|
| HIV Infections | 3 | 2016 | 17165 | 0.160 |
Why?
|
| Aging | 2 | 2016 | 8651 | 0.160 |
Why?
|
| Uricosuric Agents | 1 | 2018 | 30 | 0.150 |
Why?
|
| Simvastatin | 2 | 2012 | 352 | 0.150 |
Why?
|
| Spine | 2 | 2019 | 1111 | 0.150 |
Why?
|
| Hepatitis B Antigens | 1 | 2017 | 39 | 0.150 |
Why?
|
| Drug Monitoring | 2 | 2019 | 965 | 0.150 |
Why?
|
| Hip | 1 | 2019 | 251 | 0.150 |
Why?
|
| Activities of Daily Living | 3 | 2005 | 2417 | 0.150 |
Why?
|
| Early Detection of Cancer | 1 | 2012 | 3202 | 0.150 |
Why?
|
| Anti-Inflammatory Agents | 3 | 2013 | 1796 | 0.150 |
Why?
|
| Republic of Korea | 2 | 2019 | 566 | 0.150 |
Why?
|
| Canada | 3 | 2012 | 2128 | 0.150 |
Why?
|
| Fatty Liver | 1 | 2024 | 778 | 0.150 |
Why?
|
| Gastrointestinal Agents | 1 | 2003 | 509 | 0.150 |
Why?
|
| Vitamin B Complex | 1 | 2020 | 297 | 0.150 |
Why?
|
| Kidney | 4 | 2021 | 7064 | 0.150 |
Why?
|
| Cardiovascular System | 1 | 2005 | 850 | 0.150 |
Why?
|
| Patient Discharge | 6 | 2014 | 3476 | 0.150 |
Why?
|
| Maryland | 1 | 2018 | 275 | 0.150 |
Why?
|
| Epidemiologic Research Design | 2 | 2013 | 368 | 0.140 |
Why?
|
| Placebos | 2 | 2020 | 1668 | 0.140 |
Why?
|
| Hepatitis B Antibodies | 1 | 2017 | 157 | 0.140 |
Why?
|
| Boston | 4 | 2017 | 9280 | 0.140 |
Why?
|
| Injections | 1 | 2020 | 830 | 0.140 |
Why?
|
| Pregnancy Complications | 1 | 2011 | 2942 | 0.140 |
Why?
|
| Range of Motion, Articular | 2 | 2019 | 1583 | 0.140 |
Why?
|
| Myocardial Revascularization | 2 | 2013 | 841 | 0.140 |
Why?
|
| Single-Blind Method | 2 | 2012 | 1578 | 0.140 |
Why?
|
| Residence Characteristics | 4 | 2019 | 2062 | 0.140 |
Why?
|
| Drug Labeling | 2 | 2009 | 251 | 0.140 |
Why?
|
| Ulna | 1 | 2017 | 134 | 0.140 |
Why?
|
| Lipoproteins, LDL | 2 | 2012 | 641 | 0.140 |
Why?
|
| Anti-Bacterial Agents | 3 | 2015 | 7408 | 0.130 |
Why?
|
| Pyrazoles | 5 | 2009 | 1999 | 0.130 |
Why?
|
| Kidney Failure, Chronic | 4 | 2011 | 2471 | 0.130 |
Why?
|
| Medical History Taking | 1 | 2000 | 773 | 0.130 |
Why?
|
| Unnecessary Procedures | 1 | 1999 | 413 | 0.130 |
Why?
|
| Fatigue | 3 | 2022 | 1544 | 0.130 |
Why?
|
| Bone Remodeling | 1 | 2019 | 580 | 0.130 |
Why?
|
| Anticonvulsants | 1 | 2005 | 1879 | 0.130 |
Why?
|
| Medication Therapy Management | 1 | 2017 | 132 | 0.130 |
Why?
|
| Cooking | 1 | 2018 | 311 | 0.130 |
Why?
|
| Vulnerable Populations | 2 | 2019 | 696 | 0.130 |
Why?
|
| Stomach Diseases | 1 | 1997 | 133 | 0.130 |
Why?
|
| Carpal Tunnel Syndrome | 1 | 1999 | 303 | 0.130 |
Why?
|
| Drug Interactions | 2 | 2015 | 1428 | 0.130 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2015 | 78 | 0.130 |
Why?
|
| Receptors, Histamine H2 | 1 | 2015 | 18 | 0.130 |
Why?
|
| Myocardial Ischemia | 2 | 2022 | 2164 | 0.130 |
Why?
|
| TNF Receptor-Associated Factor 1 | 1 | 2015 | 50 | 0.120 |
Why?
|
| Estrogen Replacement Therapy | 4 | 2011 | 1206 | 0.120 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2020 | 20509 | 0.120 |
Why?
|
| Medical Audit | 3 | 2008 | 452 | 0.120 |
Why?
|
| Intention to Treat Analysis | 4 | 2018 | 422 | 0.120 |
Why?
|
| Minority Groups | 2 | 2013 | 1201 | 0.120 |
Why?
|
| Clarithromycin | 1 | 2015 | 85 | 0.120 |
Why?
|
| Nutritive Value | 1 | 2018 | 349 | 0.120 |
Why?
|
| Peptides, Cyclic | 3 | 2012 | 392 | 0.120 |
Why?
|
| Sleep | 2 | 2021 | 4751 | 0.120 |
Why?
|
| Meta-Analysis as Topic | 1 | 2020 | 1376 | 0.120 |
Why?
|
| Vaccination | 1 | 2007 | 3361 | 0.120 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 1999 | 707 | 0.120 |
Why?
|
| Thyrotropin | 20 | 1993 | 832 | 0.120 |
Why?
|
| Reminder Systems | 2 | 2011 | 387 | 0.120 |
Why?
|
| Utilization Review | 5 | 2003 | 383 | 0.120 |
Why?
|
| Regional Blood Flow | 1 | 2018 | 1490 | 0.120 |
Why?
|
| Wrist Injuries | 1 | 2017 | 214 | 0.120 |
Why?
|
| Anti-Ulcer Agents | 2 | 2018 | 113 | 0.120 |
Why?
|
| Physician's Role | 3 | 2011 | 918 | 0.120 |
Why?
|
| Leptin | 2 | 2012 | 1591 | 0.120 |
Why?
|
| Radius | 1 | 2017 | 440 | 0.120 |
Why?
|
| Medical Record Linkage | 1 | 2015 | 288 | 0.120 |
Why?
|
| Cyclophosphamide | 2 | 2017 | 2221 | 0.110 |
Why?
|
| Hematinics | 1 | 2017 | 281 | 0.110 |
Why?
|
| Health Services Research | 4 | 2015 | 1810 | 0.110 |
Why?
|
| Blood Glucose | 2 | 2023 | 6381 | 0.110 |
Why?
|
| Calcinosis | 1 | 2022 | 1476 | 0.110 |
Why?
|
| Aortitis | 1 | 2014 | 74 | 0.110 |
Why?
|
| Imidazoles | 2 | 2017 | 1180 | 0.110 |
Why?
|
| Measles | 1 | 2015 | 185 | 0.110 |
Why?
|
| Research Report | 1 | 2016 | 370 | 0.110 |
Why?
|
| Radioimmunoassay | 13 | 1993 | 866 | 0.110 |
Why?
|
| Brazil | 1 | 2017 | 1218 | 0.110 |
Why?
|
| Biomedical Research | 4 | 2017 | 3426 | 0.110 |
Why?
|
| Critical Pathways | 2 | 2010 | 475 | 0.110 |
Why?
|
| Polypharmacy | 2 | 2006 | 307 | 0.110 |
Why?
|
| Endarterectomy | 2 | 1990 | 195 | 0.110 |
Why?
|
| Vaginal Smears | 2 | 2014 | 495 | 0.110 |
Why?
|
| Rheumatic Fever | 1 | 2013 | 75 | 0.110 |
Why?
|
| Carbonated Beverages | 1 | 2014 | 209 | 0.110 |
Why?
|
| Qualitative Research | 4 | 2021 | 2963 | 0.110 |
Why?
|
| Economic Competition | 1 | 2015 | 218 | 0.110 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2024 | 15789 | 0.100 |
Why?
|
| Remote Consultation | 2 | 2020 | 234 | 0.100 |
Why?
|
| Densitometry | 2 | 2004 | 151 | 0.100 |
Why?
|
| Cyclohexanols | 1 | 2013 | 126 | 0.100 |
Why?
|
| Waiting Lists | 1 | 2017 | 763 | 0.100 |
Why?
|
| Dietary Sucrose | 1 | 2014 | 244 | 0.100 |
Why?
|
| Thyroid Hormones | 6 | 1987 | 403 | 0.100 |
Why?
|
| Cause of Death | 4 | 2018 | 3725 | 0.100 |
Why?
|
| Thyroid Function Tests | 7 | 1987 | 289 | 0.100 |
Why?
|
| Counseling | 2 | 2011 | 1548 | 0.100 |
Why?
|
| Hyperthyroidism | 13 | 1988 | 291 | 0.100 |
Why?
|
| Ipodate | 4 | 1985 | 8 | 0.100 |
Why?
|
| Multicenter Studies as Topic | 2 | 2007 | 1722 | 0.100 |
Why?
|
| Resistin | 1 | 2012 | 172 | 0.100 |
Why?
|
| North America | 1 | 2015 | 1284 | 0.100 |
Why?
|
| Atherosclerosis | 3 | 2018 | 3517 | 0.100 |
Why?
|
| Microsomes | 6 | 1992 | 252 | 0.100 |
Why?
|
| Azetidines | 1 | 2012 | 141 | 0.100 |
Why?
|
| Early Diagnosis | 2 | 2018 | 1180 | 0.100 |
Why?
|
| Sertraline | 1 | 2013 | 208 | 0.100 |
Why?
|
| Lipoproteins | 2 | 2013 | 882 | 0.100 |
Why?
|
| Goals | 1 | 2016 | 708 | 0.100 |
Why?
|
| Synovial Membrane | 1 | 2014 | 524 | 0.090 |
Why?
|
| Information Storage and Retrieval | 1 | 2017 | 822 | 0.090 |
Why?
|
| Flow Cytometry | 1 | 2022 | 5870 | 0.090 |
Why?
|
| Dextropropoxyphene | 1 | 2010 | 26 | 0.090 |
Why?
|
| Coronary Angiography | 5 | 2007 | 4563 | 0.090 |
Why?
|
| Frail Elderly | 2 | 2010 | 752 | 0.090 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2015 | 1523 | 0.090 |
Why?
|
| Patient Preference | 1 | 2018 | 922 | 0.090 |
Why?
|
| Arthroscopy | 2 | 2012 | 960 | 0.090 |
Why?
|
| Drug Industry | 2 | 2010 | 789 | 0.090 |
Why?
|
| Anti-Anxiety Agents | 1 | 2013 | 397 | 0.090 |
Why?
|
| Hydrocodone | 1 | 2010 | 48 | 0.090 |
Why?
|
| Postoperative Complications | 6 | 2019 | 15697 | 0.090 |
Why?
|
| Streptococcus pyogenes | 1 | 2013 | 294 | 0.090 |
Why?
|
| Forecasting | 4 | 2008 | 2932 | 0.090 |
Why?
|
| Codeine | 1 | 2010 | 51 | 0.090 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2012 | 150 | 0.090 |
Why?
|
| DNA, Viral | 1 | 2017 | 2194 | 0.090 |
Why?
|
| Pyrimidines | 2 | 2015 | 3016 | 0.090 |
Why?
|
| Pain, Intractable | 1 | 2011 | 132 | 0.090 |
Why?
|
| Herpes Zoster | 1 | 2013 | 251 | 0.090 |
Why?
|
| Immune System Diseases | 1 | 2013 | 258 | 0.090 |
Why?
|
| Optic Neuritis | 1 | 2012 | 174 | 0.090 |
Why?
|
| Ultrasonography | 2 | 2021 | 5961 | 0.090 |
Why?
|
| Arthritis, Gouty | 1 | 2010 | 28 | 0.090 |
Why?
|
| Preoperative Care | 1 | 2019 | 2256 | 0.090 |
Why?
|
| Steroids | 1 | 2015 | 928 | 0.090 |
Why?
|
| Thyroxine-Binding Proteins | 4 | 1986 | 25 | 0.090 |
Why?
|
| Off-Label Use | 1 | 2012 | 184 | 0.090 |
Why?
|
| Analysis of Variance | 4 | 2017 | 6238 | 0.090 |
Why?
|
| Random Allocation | 3 | 2004 | 2394 | 0.090 |
Why?
|
| Drug Recalls | 1 | 2009 | 20 | 0.090 |
Why?
|
| Cooperative Behavior | 1 | 2017 | 1500 | 0.090 |
Why?
|
| Joints | 1 | 2011 | 321 | 0.090 |
Why?
|
| Survival Rate | 4 | 2020 | 12808 | 0.090 |
Why?
|
| Fibrinolytic Agents | 3 | 2010 | 2167 | 0.090 |
Why?
|
| Device Approval | 1 | 2011 | 165 | 0.090 |
Why?
|
| Carotid Stenosis | 2 | 1996 | 878 | 0.090 |
Why?
|
| Wrist Joint | 2 | 2023 | 265 | 0.080 |
Why?
|
| Prosthesis Failure | 2 | 2013 | 1206 | 0.080 |
Why?
|
| Veterans | 2 | 2022 | 2642 | 0.080 |
Why?
|
| Drug Therapy | 3 | 2012 | 504 | 0.080 |
Why?
|
| Mental Disorders | 2 | 2012 | 6796 | 0.080 |
Why?
|
| Demography | 1 | 2014 | 1650 | 0.080 |
Why?
|
| Renal Replacement Therapy | 1 | 2011 | 281 | 0.080 |
Why?
|
| Reference Values | 3 | 2015 | 4925 | 0.080 |
Why?
|
| Carotid Arteries | 2 | 1990 | 951 | 0.080 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2010 | 356 | 0.080 |
Why?
|
| Physical Therapy Modalities | 1 | 2013 | 536 | 0.080 |
Why?
|
| Markov Chains | 1 | 2013 | 968 | 0.080 |
Why?
|
| Mammography | 2 | 2012 | 2427 | 0.080 |
Why?
|
| Consensus | 1 | 2019 | 3113 | 0.080 |
Why?
|
| Acute Coronary Syndrome | 1 | 2022 | 2365 | 0.080 |
Why?
|
| Blood Proteins | 3 | 1987 | 1173 | 0.080 |
Why?
|
| Australia | 1 | 2013 | 1289 | 0.080 |
Why?
|
| Community Pharmacy Services | 1 | 2009 | 50 | 0.080 |
Why?
|
| Hydrochlorothiazide | 1 | 2009 | 94 | 0.080 |
Why?
|
| Probability | 3 | 2022 | 2475 | 0.080 |
Why?
|
| Cholesterol, HDL | 1 | 2015 | 1817 | 0.080 |
Why?
|
| Mandible | 1 | 2013 | 750 | 0.080 |
Why?
|
| Medicine | 5 | 2009 | 943 | 0.080 |
Why?
|
| Depression | 2 | 2019 | 8044 | 0.080 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2010 | 225 | 0.080 |
Why?
|
| Hospitals | 7 | 2010 | 3928 | 0.080 |
Why?
|
| Hospital Bed Capacity | 1 | 2009 | 210 | 0.080 |
Why?
|
| Health Services | 3 | 2012 | 753 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2024 | 17790 | 0.080 |
Why?
|
| Sulfinpyrazone | 1 | 2007 | 15 | 0.080 |
Why?
|
| Pulmonary Embolism | 1 | 2021 | 2543 | 0.080 |
Why?
|
| Epidemiologic Factors | 1 | 2007 | 36 | 0.080 |
Why?
|
| Virus Activation | 1 | 2010 | 319 | 0.080 |
Why?
|
| Genome-Wide Association Study | 2 | 2024 | 12626 | 0.070 |
Why?
|
| Legislation, Drug | 1 | 2010 | 214 | 0.070 |
Why?
|
| Health Benefit Plans, Employee | 1 | 2010 | 333 | 0.070 |
Why?
|
| Community Health Services | 2 | 2012 | 654 | 0.070 |
Why?
|
| Carcinoma in Situ | 1 | 2013 | 796 | 0.070 |
Why?
|
| HLA-DR4 Antigen | 1 | 2007 | 29 | 0.070 |
Why?
|
| Phenotype | 3 | 2015 | 16546 | 0.070 |
Why?
|
| Efficiency, Organizational | 1 | 2012 | 697 | 0.070 |
Why?
|
| Learning | 1 | 2017 | 1739 | 0.070 |
Why?
|
| Management Information Systems | 1 | 2007 | 49 | 0.070 |
Why?
|
| American Medical Association | 1 | 2007 | 60 | 0.070 |
Why?
|
| Biological Assay | 8 | 2021 | 630 | 0.070 |
Why?
|
| Dyslipidemias | 1 | 2015 | 895 | 0.070 |
Why?
|
| Body Weight | 3 | 2017 | 4611 | 0.070 |
Why?
|
| Population | 1 | 2007 | 140 | 0.070 |
Why?
|
| Fractures, Compression | 1 | 2009 | 129 | 0.070 |
Why?
|
| Placebo Effect | 1 | 2011 | 520 | 0.070 |
Why?
|
| Analgesia | 1 | 2011 | 459 | 0.070 |
Why?
|
| England | 1 | 2008 | 526 | 0.070 |
Why?
|
| Home Care Services | 1 | 1993 | 654 | 0.070 |
Why?
|
| Aorta | 1 | 2014 | 2039 | 0.070 |
Why?
|
| Pilot Projects | 3 | 2018 | 8555 | 0.070 |
Why?
|
| Medical Staff, Hospital | 2 | 2001 | 600 | 0.070 |
Why?
|
| Prescription Fees | 1 | 2007 | 151 | 0.070 |
Why?
|
| Occult Blood | 1 | 2007 | 197 | 0.070 |
Why?
|
| Antithyroid Agents | 2 | 1985 | 72 | 0.070 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 2 | 2004 | 318 | 0.070 |
Why?
|
| Prejudice | 1 | 2010 | 563 | 0.070 |
Why?
|
| Humerus | 2 | 2010 | 269 | 0.070 |
Why?
|
| Radius Fractures | 2 | 2010 | 513 | 0.070 |
Why?
|
| Abortion, Spontaneous | 1 | 2011 | 530 | 0.070 |
Why?
|
| Immunoconjugates | 1 | 2013 | 949 | 0.070 |
Why?
|
| Health Educators | 1 | 2005 | 19 | 0.070 |
Why?
|
| Interleukin-6 | 2 | 2018 | 3215 | 0.060 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2014 | 2007 | 0.060 |
Why?
|
| Diiodothyronines | 3 | 1979 | 5 | 0.060 |
Why?
|
| Professional-Patient Relations | 1 | 2011 | 726 | 0.060 |
Why?
|
| Antiviral Agents | 1 | 2018 | 3061 | 0.060 |
Why?
|
| Longevity | 1 | 2013 | 1050 | 0.060 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 2717 | 0.060 |
Why?
|
| Clinical Trials as Topic | 3 | 2012 | 8056 | 0.060 |
Why?
|
| Income | 1 | 2014 | 1875 | 0.060 |
Why?
|
| Biopsy | 1 | 2017 | 6771 | 0.060 |
Why?
|
| Ofloxacin | 2 | 2003 | 66 | 0.060 |
Why?
|
| Medical Assistance | 1 | 2005 | 107 | 0.060 |
Why?
|
| Vitamin D | 1 | 2019 | 3291 | 0.060 |
Why?
|
| Cost Savings | 1 | 2010 | 920 | 0.060 |
Why?
|
| Technology Assessment, Biomedical | 2 | 2003 | 306 | 0.060 |
Why?
|
| Clinical Competence | 3 | 2009 | 4783 | 0.060 |
Why?
|
| Breast Neoplasms | 1 | 2012 | 21025 | 0.060 |
Why?
|
| Administration, Inhalation | 1 | 2008 | 1156 | 0.060 |
Why?
|
| Bacterial Vaccines | 1 | 2007 | 401 | 0.060 |
Why?
|
| Hemoglobins | 1 | 2010 | 1521 | 0.060 |
Why?
|
| Radiopharmaceuticals | 1 | 2014 | 2634 | 0.060 |
Why?
|
| Life Expectancy | 1 | 2011 | 1248 | 0.060 |
Why?
|
| Cyclooxygenase 2 | 2 | 2004 | 599 | 0.060 |
Why?
|
| Risk Reduction Behavior | 1 | 2011 | 1109 | 0.060 |
Why?
|
| Health Education | 1 | 2011 | 1049 | 0.060 |
Why?
|
| Hospitals, Veterans | 1 | 2006 | 398 | 0.060 |
Why?
|
| Formularies as Topic | 1 | 2004 | 93 | 0.060 |
Why?
|
| Patient Care Team | 1 | 2015 | 2511 | 0.060 |
Why?
|
| Allied Health Personnel | 1 | 2005 | 156 | 0.060 |
Why?
|
| Consumer Product Safety | 1 | 2005 | 123 | 0.060 |
Why?
|
| Hospital Records | 1 | 2004 | 93 | 0.060 |
Why?
|
| Sample Size | 1 | 2007 | 840 | 0.060 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2013 | 911 | 0.060 |
Why?
|
| Surgical Procedures, Operative | 2 | 2005 | 1913 | 0.060 |
Why?
|
| Anti-Retroviral Agents | 1 | 2013 | 1779 | 0.060 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2006 | 389 | 0.060 |
Why?
|
| Pharmacogenetics | 1 | 2008 | 680 | 0.060 |
Why?
|
| Shoulder Joint | 2 | 2001 | 732 | 0.060 |
Why?
|
| Cost Control | 1 | 2006 | 630 | 0.060 |
Why?
|
| Creatine Kinase, MB Form | 1 | 2004 | 211 | 0.060 |
Why?
|
| Polysaccharides | 1 | 2010 | 1016 | 0.060 |
Why?
|
| SEER Program | 1 | 2009 | 1530 | 0.060 |
Why?
|
| Drugs, Generic | 1 | 2009 | 448 | 0.060 |
Why?
|
| Skin | 1 | 2017 | 4466 | 0.060 |
Why?
|
| Length of Stay | 4 | 2010 | 6479 | 0.060 |
Why?
|
| Geriatrics | 1 | 1988 | 387 | 0.050 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 1985 | 393 | 0.050 |
Why?
|
| Endpoint Determination | 1 | 2006 | 597 | 0.050 |
Why?
|
| Medication Errors | 1 | 2009 | 784 | 0.050 |
Why?
|
| Creatinine | 2 | 2007 | 1903 | 0.050 |
Why?
|
| Pre-Eclampsia | 1 | 2012 | 1229 | 0.050 |
Why?
|
| Disease-Free Survival | 2 | 2010 | 6828 | 0.050 |
Why?
|
| Heparin | 1 | 2010 | 1652 | 0.050 |
Why?
|
| Norway | 1 | 2024 | 496 | 0.050 |
Why?
|
| Ambulatory Care | 2 | 2013 | 2781 | 0.050 |
Why?
|
| Internet | 2 | 2012 | 3078 | 0.050 |
Why?
|
| Diagnostic Errors | 2 | 2009 | 1266 | 0.050 |
Why?
|
| Creatine Kinase | 1 | 2004 | 691 | 0.050 |
Why?
|
| Drug Therapy, Computer-Assisted | 1 | 2003 | 198 | 0.050 |
Why?
|
| Indians, North American | 2 | 2018 | 350 | 0.050 |
Why?
|
| Control Groups | 1 | 2022 | 104 | 0.050 |
Why?
|
| Radiology Department, Hospital | 1 | 2006 | 405 | 0.050 |
Why?
|
| Reimbursement, Incentive | 1 | 2007 | 542 | 0.050 |
Why?
|
| History, 20th Century | 1 | 2010 | 2773 | 0.050 |
Why?
|
| Puerto Rico | 1 | 2003 | 373 | 0.050 |
Why?
|
| Hypothyroidism | 9 | 1988 | 665 | 0.050 |
Why?
|
| Self-Help Groups | 1 | 2003 | 189 | 0.050 |
Why?
|
| Pandemics | 1 | 2022 | 8624 | 0.050 |
Why?
|
| Ceftazidime | 1 | 2001 | 57 | 0.050 |
Why?
|
| Vitamin B 12 | 1 | 2004 | 522 | 0.050 |
Why?
|
| Connective Tissue Diseases | 1 | 2024 | 286 | 0.050 |
Why?
|
| Suicide, Attempted | 1 | 2010 | 1378 | 0.050 |
Why?
|
| Public Health | 2 | 2012 | 2653 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2003 | 36290 | 0.050 |
Why?
|
| Genotype | 1 | 2015 | 12960 | 0.050 |
Why?
|
| Posterior Cruciate Ligament | 1 | 2001 | 85 | 0.050 |
Why?
|
| Shoulder | 1 | 2003 | 299 | 0.050 |
Why?
|
| Incidental Findings | 1 | 2006 | 698 | 0.050 |
Why?
|
| Observer Variation | 1 | 2007 | 2601 | 0.050 |
Why?
|
| Reference Standards | 1 | 2004 | 1004 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 3 | 2002 | 2471 | 0.040 |
Why?
|
| Anti-HIV Agents | 2 | 2016 | 4491 | 0.040 |
Why?
|
| Troponin | 1 | 2004 | 516 | 0.040 |
Why?
|
| Cultural Diversity | 1 | 2024 | 365 | 0.040 |
Why?
|
| Medical Records, Problem-Oriented | 1 | 2000 | 35 | 0.040 |
Why?
|
| Cephalosporins | 1 | 2001 | 204 | 0.040 |
Why?
|
| Pregnancy | 10 | 2012 | 29749 | 0.040 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2002 | 288 | 0.040 |
Why?
|
| Fractional Flow Reserve, Myocardial | 1 | 2024 | 329 | 0.040 |
Why?
|
| False Positive Reactions | 1 | 2002 | 956 | 0.040 |
Why?
|
| New England | 1 | 2003 | 1050 | 0.040 |
Why?
|
| Insurance Carriers | 1 | 2021 | 156 | 0.040 |
Why?
|
| Thyroid Diseases | 4 | 1999 | 386 | 0.040 |
Why?
|
| Influenza Vaccines | 1 | 2007 | 766 | 0.040 |
Why?
|
| Antibodies | 6 | 2012 | 2421 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2024 | 1871 | 0.040 |
Why?
|
| Radiography, Thoracic | 1 | 2006 | 1296 | 0.040 |
Why?
|
| Scleroderma, Systemic | 1 | 2003 | 344 | 0.040 |
Why?
|
| Neuralgia | 2 | 2019 | 600 | 0.040 |
Why?
|
| Multiple Sclerosis | 1 | 2014 | 3204 | 0.040 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2000 | 426 | 0.040 |
Why?
|
| Child, Preschool | 5 | 2013 | 42063 | 0.040 |
Why?
|
| Troponin T | 1 | 2024 | 774 | 0.040 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2024 | 998 | 0.040 |
Why?
|
| Discriminant Analysis | 1 | 1999 | 223 | 0.040 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2016 | 8950 | 0.040 |
Why?
|
| Statistics, Nonparametric | 2 | 2018 | 2852 | 0.040 |
Why?
|
| Immunoenzyme Techniques | 2 | 2000 | 1705 | 0.040 |
Why?
|
| Bone and Bones | 2 | 2007 | 2560 | 0.040 |
Why?
|
| Thyrotropin-Releasing Hormone | 5 | 1977 | 139 | 0.040 |
Why?
|
| Health Status Indicators | 1 | 2004 | 968 | 0.040 |
Why?
|
| Triiodothyronine, Reverse | 6 | 1985 | 23 | 0.040 |
Why?
|
| Diabetic Nephropathies | 1 | 2005 | 988 | 0.040 |
Why?
|
| Dexamethasone | 2 | 1975 | 1927 | 0.040 |
Why?
|
| Asthma | 2 | 2009 | 6172 | 0.040 |
Why?
|
| Stents | 1 | 2010 | 3314 | 0.040 |
Why?
|
| Transaminases | 1 | 2018 | 196 | 0.040 |
Why?
|
| Homes for the Aged | 2 | 2012 | 272 | 0.040 |
Why?
|
| Psychometrics | 1 | 2007 | 3051 | 0.040 |
Why?
|
| Synovial Fluid | 1 | 2020 | 395 | 0.040 |
Why?
|
| Personal Satisfaction | 1 | 2022 | 643 | 0.040 |
Why?
|
| Information Systems | 1 | 1999 | 398 | 0.040 |
Why?
|
| Warfarin | 1 | 2006 | 1518 | 0.040 |
Why?
|
| Societies, Medical | 2 | 2008 | 3905 | 0.040 |
Why?
|
| Recovery of Function | 2 | 2013 | 2985 | 0.040 |
Why?
|
| Drug Resistance, Microbial | 1 | 2000 | 856 | 0.040 |
Why?
|
| Prostate-Specific Antigen | 1 | 2007 | 2529 | 0.040 |
Why?
|
| Troponin I | 1 | 2001 | 638 | 0.040 |
Why?
|
| Animals | 16 | 2018 | 167963 | 0.040 |
Why?
|
| Causality | 1 | 2023 | 1242 | 0.040 |
Why?
|
| Attitude of Health Personnel | 1 | 2011 | 3865 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2019 | 555 | 0.040 |
Why?
|
| Colitis, Ulcerative | 1 | 2009 | 1919 | 0.030 |
Why?
|
| Immunity, Cellular | 1 | 2023 | 1557 | 0.030 |
Why?
|
| Computational Biology | 1 | 2009 | 3505 | 0.030 |
Why?
|
| Fever | 2 | 2013 | 1617 | 0.030 |
Why?
|
| Geography | 1 | 2019 | 661 | 0.030 |
Why?
|
| Blood | 4 | 1974 | 586 | 0.030 |
Why?
|
| Complement System Proteins | 1 | 1999 | 782 | 0.030 |
Why?
|
| Penicillamine | 1 | 2016 | 60 | 0.030 |
Why?
|
| Hospitals, Teaching | 1 | 2001 | 1166 | 0.030 |
Why?
|
| Crohn Disease | 1 | 2009 | 2275 | 0.030 |
Why?
|
| Culture | 1 | 2000 | 622 | 0.030 |
Why?
|
| Autoimmunity | 1 | 2024 | 1370 | 0.030 |
Why?
|
| Hemophilia A | 1 | 2019 | 359 | 0.030 |
Why?
|
| Cerebrovascular Disorders | 2 | 1995 | 1501 | 0.030 |
Why?
|
| ROC Curve | 1 | 2024 | 3568 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2020 | 1636 | 0.030 |
Why?
|
| Infant | 3 | 2013 | 36060 | 0.030 |
Why?
|
| Monte Carlo Method | 2 | 2013 | 1257 | 0.030 |
Why?
|
| Oleic Acids | 2 | 1986 | 74 | 0.030 |
Why?
|
| Administration, Topical | 1 | 2017 | 697 | 0.030 |
Why?
|
| Selection Bias | 1 | 1997 | 358 | 0.030 |
Why?
|
| Autoantigens | 1 | 2000 | 877 | 0.030 |
Why?
|
| Life Style | 1 | 2007 | 3896 | 0.030 |
Why?
|
| Child | 7 | 2013 | 79806 | 0.030 |
Why?
|
| Hematologic Neoplasms | 1 | 2007 | 1895 | 0.030 |
Why?
|
| Back Pain | 1 | 2019 | 543 | 0.030 |
Why?
|
| Depressive Disorder, Major | 1 | 2013 | 4744 | 0.030 |
Why?
|
| Minocycline | 1 | 2016 | 168 | 0.030 |
Why?
|
| Pancreatitis | 1 | 2002 | 1100 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2003 | 2493 | 0.030 |
Why?
|
| Protein-Energy Malnutrition | 1 | 1975 | 188 | 0.030 |
Why?
|
| Patient Admission | 3 | 2009 | 1386 | 0.030 |
Why?
|
| Nonprescription Drugs | 1 | 2015 | 118 | 0.030 |
Why?
|
| Diagnostic Imaging | 1 | 2009 | 3527 | 0.030 |
Why?
|
| Immunoglobulin M | 1 | 1979 | 1529 | 0.030 |
Why?
|
| Endocrinology | 1 | 2000 | 443 | 0.030 |
Why?
|
| Antistreptolysin | 1 | 2013 | 6 | 0.030 |
Why?
|
| Iodine | 4 | 1970 | 286 | 0.030 |
Why?
|
| Anti-Infective Agents | 1 | 2001 | 981 | 0.030 |
Why?
|
| Irritable Bowel Syndrome | 1 | 2019 | 453 | 0.030 |
Why?
|
| Protein Binding | 8 | 1987 | 9335 | 0.030 |
Why?
|
| Teaching | 1 | 2001 | 1169 | 0.030 |
Why?
|
| Alcoholism | 2 | 1984 | 1961 | 0.030 |
Why?
|
| Clinical Laboratory Techniques | 1 | 1998 | 749 | 0.030 |
Why?
|
| Outpatients | 2 | 2011 | 1607 | 0.030 |
Why?
|
| Cartilage, Articular | 1 | 2020 | 1091 | 0.030 |
Why?
|
| Publication Bias | 1 | 2013 | 162 | 0.030 |
Why?
|
| Iodide Peroxidase | 2 | 1992 | 294 | 0.030 |
Why?
|
| Internal Medicine | 1 | 2000 | 1048 | 0.030 |
Why?
|
| Models, Econometric | 1 | 2013 | 216 | 0.030 |
Why?
|
| Health Services Misuse | 3 | 1990 | 245 | 0.030 |
Why?
|
| Antipsychotic Agents | 1 | 2005 | 3061 | 0.030 |
Why?
|
| Patient Readmission | 2 | 2019 | 3323 | 0.030 |
Why?
|
| American Recovery and Reinvestment Act | 1 | 2012 | 72 | 0.030 |
Why?
|
| Kidney Transplantation | 3 | 2011 | 4215 | 0.020 |
Why?
|
| Biological Therapy | 1 | 2013 | 139 | 0.020 |
Why?
|
| Epigenomics | 1 | 2018 | 936 | 0.020 |
Why?
|
| Prolactin | 1 | 1974 | 621 | 0.020 |
Why?
|
| Thyroglobulin | 3 | 1993 | 111 | 0.020 |
Why?
|
| Health Planning | 1 | 1993 | 232 | 0.020 |
Why?
|
| Clinical Coding | 1 | 2013 | 181 | 0.020 |
Why?
|
| Immune Sera | 3 | 1971 | 613 | 0.020 |
Why?
|
| Communication | 1 | 2006 | 3849 | 0.020 |
Why?
|
| Renal Dialysis | 2 | 2011 | 1801 | 0.020 |
Why?
|
| Tennessee | 1 | 2011 | 119 | 0.020 |
Why?
|
| Pain, Postoperative | 1 | 2022 | 1721 | 0.020 |
Why?
|
| Propylthiouracil | 5 | 1982 | 68 | 0.020 |
Why?
|
| Systems Theory | 1 | 2011 | 57 | 0.020 |
Why?
|
| Filgrastim | 1 | 2011 | 132 | 0.020 |
Why?
|
| Dialysis | 3 | 1986 | 75 | 0.020 |
Why?
|
| Thyroiditis | 3 | 1973 | 86 | 0.020 |
Why?
|
| Naphthalenes | 1 | 2012 | 198 | 0.020 |
Why?
|
| Mitral Valve Stenosis | 1 | 2013 | 348 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2024 | 4742 | 0.020 |
Why?
|
| Orthopedics | 1 | 2000 | 892 | 0.020 |
Why?
|
| Health Planning Guidelines | 1 | 2011 | 151 | 0.020 |
Why?
|
| Occupational Diseases | 1 | 1999 | 1486 | 0.020 |
Why?
|
| Complement Fixation Tests | 2 | 1968 | 71 | 0.020 |
Why?
|
| Cyclic AMP | 1 | 1975 | 1456 | 0.020 |
Why?
|
| Adaptation, Psychological | 1 | 2021 | 2628 | 0.020 |
Why?
|
| Liver Diseases | 1 | 1979 | 1302 | 0.020 |
Why?
|
| Peritoneal Dialysis | 1 | 2011 | 157 | 0.020 |
Why?
|
| Respiratory Tract Diseases | 1 | 2016 | 748 | 0.020 |
Why?
|
| Pulmonary Edema | 1 | 2013 | 409 | 0.020 |
Why?
|
| Mortality | 2 | 2012 | 2916 | 0.020 |
Why?
|
| Fluvoxamine | 1 | 2010 | 78 | 0.020 |
Why?
|
| Alleles | 2 | 2015 | 6898 | 0.020 |
Why?
|
| Social Class | 1 | 2019 | 2005 | 0.020 |
Why?
|
| Chromatography, Gas | 2 | 1985 | 151 | 0.020 |
Why?
|
| Ontario | 1 | 2011 | 404 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2016 | 2569 | 0.020 |
Why?
|
| Gastrointestinal Tract | 2 | 2006 | 830 | 0.020 |
Why?
|
| Membrane Proteins | 2 | 2004 | 7850 | 0.020 |
Why?
|
| Isoxazoles | 1 | 2011 | 230 | 0.020 |
Why?
|
| Clinical Audit | 1 | 2009 | 30 | 0.020 |
Why?
|
| Organizational Case Studies | 1 | 2010 | 301 | 0.020 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2018 | 1717 | 0.020 |
Why?
|
| Case Management | 1 | 2011 | 272 | 0.020 |
Why?
|
| Paroxetine | 1 | 2010 | 182 | 0.020 |
Why?
|
| Vitamin D Deficiency | 1 | 2019 | 1379 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2013 | 1600 | 0.020 |
Why?
|
| Ulna Fractures | 1 | 2010 | 126 | 0.020 |
Why?
|
| Minnesota | 1 | 2009 | 340 | 0.020 |
Why?
|
| Nuclear Proteins | 2 | 2003 | 5791 | 0.020 |
Why?
|
| Cost Sharing | 1 | 2012 | 410 | 0.020 |
Why?
|
| Stroke Volume | 1 | 2022 | 5523 | 0.020 |
Why?
|
| Lidocaine | 1 | 2012 | 538 | 0.020 |
Why?
|
| Sulfatases | 1 | 1988 | 44 | 0.020 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2014 | 628 | 0.020 |
Why?
|
| Combined Modality Therapy | 3 | 2008 | 8552 | 0.020 |
Why?
|
| Programming Languages | 1 | 2009 | 128 | 0.020 |
Why?
|
| Oleic Acid | 2 | 1986 | 92 | 0.020 |
Why?
|
| Statistics as Topic | 2 | 2008 | 2362 | 0.020 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2011 | 629 | 0.020 |
Why?
|
| Phospholipids | 1 | 1992 | 789 | 0.020 |
Why?
|
| Endoscopy | 2 | 1988 | 1838 | 0.020 |
Why?
|
| Goiter | 4 | 1973 | 87 | 0.020 |
Why?
|
| Antibody Specificity | 2 | 1988 | 1060 | 0.020 |
Why?
|
| Hepatitis C, Chronic | 1 | 2016 | 1031 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2023 | 12766 | 0.020 |
Why?
|
| Protein Kinases | 1 | 1975 | 1612 | 0.020 |
Why?
|
| Medicare Part C | 1 | 2012 | 322 | 0.020 |
Why?
|
| Chromatography, Gel | 4 | 1992 | 645 | 0.020 |
Why?
|
| Receptors, Thyrotropin | 1 | 1987 | 45 | 0.020 |
Why?
|
| Triglycerides | 1 | 2015 | 2476 | 0.020 |
Why?
|
| Citalopram | 1 | 2010 | 402 | 0.020 |
Why?
|
| Glucuronidase | 1 | 1988 | 202 | 0.020 |
Why?
|
| Acetates | 1 | 1988 | 321 | 0.020 |
Why?
|
| Ticlopidine | 1 | 2012 | 895 | 0.020 |
Why?
|
| Health Services Needs and Demand | 1 | 2015 | 1399 | 0.020 |
Why?
|
| Economics, Hospital | 1 | 2009 | 212 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2012 | 2025 | 0.020 |
Why?
|
| Complementarity Determining Regions | 1 | 2007 | 149 | 0.020 |
Why?
|
| Emergency Service, Hospital | 2 | 2016 | 7818 | 0.020 |
Why?
|
| Energy Intake | 1 | 2014 | 2129 | 0.020 |
Why?
|
| Psychoses, Substance-Induced | 1 | 1967 | 99 | 0.020 |
Why?
|
| Americas | 1 | 2006 | 111 | 0.020 |
Why?
|
| Computers | 1 | 2009 | 595 | 0.020 |
Why?
|
| Diclofenac | 1 | 2006 | 67 | 0.020 |
Why?
|
| Insurance, Physician Services | 1 | 1986 | 23 | 0.020 |
Why?
|
| Methods | 6 | 1972 | 1074 | 0.020 |
Why?
|
| Thiazoles | 1 | 2013 | 1511 | 0.020 |
Why?
|
| Fluoxetine | 1 | 2010 | 733 | 0.020 |
Why?
|
| Radioligand Assay | 2 | 1984 | 366 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2019 | 3392 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2012 | 1677 | 0.020 |
Why?
|
| Iodine Isotopes | 5 | 1973 | 86 | 0.020 |
Why?
|
| Software | 2 | 2011 | 4419 | 0.020 |
Why?
|
| Confidentiality | 1 | 2010 | 609 | 0.020 |
Why?
|
| Infant, Newborn | 6 | 2013 | 26181 | 0.020 |
Why?
|
| Diagnosis, Differential | 4 | 2013 | 12965 | 0.020 |
Why?
|
| Geriatric Assessment | 1 | 1993 | 1405 | 0.020 |
Why?
|
| Self Administration | 1 | 2007 | 390 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2018 | 5125 | 0.020 |
Why?
|
| Diuretics | 1 | 2009 | 613 | 0.020 |
Why?
|
| Histocompatibility Testing | 1 | 2007 | 717 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2011 | 1189 | 0.020 |
Why?
|
| Chemical Precipitation | 2 | 1979 | 176 | 0.020 |
Why?
|
| Employment | 1 | 2011 | 1112 | 0.020 |
Why?
|
| Angiography | 1 | 1990 | 1605 | 0.020 |
Why?
|
| Societies, Scientific | 1 | 2006 | 221 | 0.020 |
Why?
|
| Benzhydryl Compounds | 1 | 2012 | 941 | 0.020 |
Why?
|
| Respiratory Sounds | 1 | 2009 | 697 | 0.020 |
Why?
|
| Rabbits | 6 | 1972 | 4773 | 0.020 |
Why?
|
| Likelihood Functions | 1 | 2008 | 987 | 0.020 |
Why?
|
| Immunization | 4 | 1970 | 1227 | 0.020 |
Why?
|
| Arachidonic Acids | 1 | 1985 | 294 | 0.010 |
Why?
|
| Anxiety | 1 | 2019 | 4538 | 0.010 |
Why?
|
| Aversive Therapy | 1 | 1984 | 5 | 0.010 |
Why?
|
| Phospholipases | 1 | 1984 | 76 | 0.010 |
Why?
|
| Adrenal Glands | 2 | 1968 | 554 | 0.010 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2011 | 1031 | 0.010 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 1990 | 867 | 0.010 |
Why?
|
| Age of Onset | 1 | 2011 | 3301 | 0.010 |
Why?
|
| Alcohol Withdrawal Delirium | 1 | 1984 | 26 | 0.010 |
Why?
|
| Ranitidine | 1 | 2003 | 34 | 0.010 |
Why?
|
| Hypercholesterolemia | 1 | 2011 | 1155 | 0.010 |
Why?
|
| Kidney Function Tests | 1 | 2006 | 681 | 0.010 |
Why?
|
| Foundations | 1 | 2004 | 97 | 0.010 |
Why?
|
| Urinary Incontinence | 1 | 1988 | 495 | 0.010 |
Why?
|
| Arachidonic Acid | 1 | 1985 | 433 | 0.010 |
Why?
|
| Social Support | 1 | 1993 | 2145 | 0.010 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2013 | 1419 | 0.010 |
Why?
|
| Thyroiditis, Autoimmune | 4 | 1978 | 101 | 0.010 |
Why?
|
| Europe | 1 | 2010 | 3441 | 0.010 |
Why?
|
| Trypsin | 1 | 1984 | 496 | 0.010 |
Why?
|
| Health Care Reform | 1 | 2012 | 1245 | 0.010 |
Why?
|
| Fluconazole | 1 | 2003 | 155 | 0.010 |
Why?
|
| Personal Health Services | 1 | 1982 | 24 | 0.010 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2003 | 108 | 0.010 |
Why?
|
| Taste Threshold | 1 | 1962 | 7 | 0.010 |
Why?
|
| Solvents | 1 | 1984 | 292 | 0.010 |
Why?
|
| Placenta | 1 | 1992 | 1702 | 0.010 |
Why?
|
| Cell Nucleolus | 1 | 2003 | 156 | 0.010 |
Why?
|
| Rats, Inbred Strains | 1 | 1984 | 2094 | 0.010 |
Why?
|
| Amniotic Fluid | 3 | 1979 | 378 | 0.010 |
Why?
|
| Continuity of Patient Care | 1 | 2009 | 1066 | 0.010 |
Why?
|
| Time and Motion Studies | 1 | 1982 | 143 | 0.010 |
Why?
|
| Mutation | 1 | 2007 | 29932 | 0.010 |
Why?
|
| Centromere | 1 | 2003 | 213 | 0.010 |
Why?
|
| Metronidazole | 1 | 2003 | 231 | 0.010 |
Why?
|
| Amiodarone | 1 | 2003 | 218 | 0.010 |
Why?
|
| Electrocardiography | 2 | 2007 | 6414 | 0.010 |
Why?
|
| Epitopes | 2 | 2007 | 2503 | 0.010 |
Why?
|
| Endocrine System Diseases | 1 | 1984 | 250 | 0.010 |
Why?
|
| Haplorhini | 3 | 1972 | 529 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2011 | 6538 | 0.010 |
Why?
|
| Adrenal Gland Diseases | 1 | 1962 | 141 | 0.010 |
Why?
|
| Long-Term Care | 1 | 1985 | 632 | 0.010 |
Why?
|
| Psychotic Disorders | 2 | 2005 | 3193 | 0.010 |
Why?
|
| Reoperation | 1 | 2011 | 4291 | 0.010 |
Why?
|
| Taste | 1 | 1962 | 188 | 0.010 |
Why?
|
| Cardiology | 1 | 2012 | 1723 | 0.010 |
Why?
|
| Internship and Residency | 1 | 2001 | 5870 | 0.010 |
Why?
|
| Iodine Radioisotopes | 5 | 1974 | 1032 | 0.010 |
Why?
|
| Echocardiography | 1 | 2013 | 4981 | 0.010 |
Why?
|
| Chromatography, Ion Exchange | 2 | 1992 | 297 | 0.010 |
Why?
|
| Adrenal Insufficiency | 1 | 1962 | 192 | 0.010 |
Why?
|
| Cell Membrane | 3 | 1976 | 3682 | 0.010 |
Why?
|
| Sodium Chloride | 1 | 1962 | 591 | 0.010 |
Why?
|
| Sodium Chloride, Dietary | 1 | 1962 | 293 | 0.010 |
Why?
|
| Skin Manifestations | 2 | 1970 | 17 | 0.010 |
Why?
|
| Immunoelectrophoresis | 2 | 1971 | 104 | 0.010 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2012 | 3201 | 0.010 |
Why?
|
| Antigens, Nuclear | 1 | 2000 | 184 | 0.010 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 1984 | 622 | 0.010 |
Why?
|
| Mood Disorders | 1 | 2005 | 1124 | 0.010 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 1978 | 64 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2003 | 2234 | 0.010 |
Why?
|
| Task Performance and Analysis | 1 | 1982 | 759 | 0.010 |
Why?
|
| Intestine, Small | 1 | 1984 | 1207 | 0.010 |
Why?
|
| Antigen-Antibody Complex | 1 | 1979 | 513 | 0.010 |
Why?
|
| Hospital Costs | 1 | 2003 | 976 | 0.010 |
Why?
|
| Binding, Competitive | 2 | 1975 | 1142 | 0.010 |
Why?
|
| Kinetics | 4 | 1992 | 6377 | 0.010 |
Why?
|
| Histocompatibility Antigens | 1 | 1977 | 467 | 0.010 |
Why?
|
| Fetal Blood | 2 | 1979 | 1343 | 0.010 |
Why?
|
| Lipid Metabolism | 1 | 1984 | 1902 | 0.010 |
Why?
|
| Delirium | 1 | 1967 | 1663 | 0.010 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2003 | 1572 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2002 | 3804 | 0.010 |
Why?
|
| Methimazole | 2 | 1970 | 41 | 0.010 |
Why?
|
| Fluorescence Polarization Immunoassay | 1 | 1993 | 9 | 0.010 |
Why?
|
| Nervous System Diseases | 1 | 1984 | 1647 | 0.010 |
Why?
|
| Serum Globulins | 1 | 1972 | 24 | 0.010 |
Why?
|
| Calcium | 1 | 2006 | 5725 | 0.010 |
Why?
|
| Cholic Acids | 1 | 1992 | 39 | 0.010 |
Why?
|
| Hot Temperature | 1 | 1979 | 1435 | 0.010 |
Why?
|
| Immunoglobulins, Thyroid-Stimulating | 2 | 1985 | 34 | 0.010 |
Why?
|
| Rats | 3 | 1985 | 23711 | 0.010 |
Why?
|
| Liver | 2 | 1984 | 7509 | 0.010 |
Why?
|
| Pituitary Hormones, Anterior | 2 | 1961 | 56 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 2 | 1988 | 1628 | 0.010 |
Why?
|
| Detergents | 1 | 1992 | 235 | 0.010 |
Why?
|
| Binding Sites | 3 | 1976 | 6048 | 0.010 |
Why?
|
| HLA Antigens | 1 | 1977 | 1368 | 0.010 |
Why?
|
| Cytosol | 1 | 1975 | 887 | 0.010 |
Why?
|
| Hemagglutination Inhibition Tests | 2 | 1968 | 86 | 0.010 |
Why?
|
| Chromatography | 1 | 1971 | 189 | 0.010 |
Why?
|
| Eye Manifestations | 1 | 1970 | 10 | 0.010 |
Why?
|
| Viscera | 2 | 1961 | 138 | 0.010 |
Why?
|
| Dementia | 1 | 2005 | 2649 | 0.010 |
Why?
|
| Stimulation, Chemical | 1 | 1970 | 306 | 0.010 |
Why?
|
| Ferritins | 1 | 1993 | 597 | 0.010 |
Why?
|
| Pulse | 2 | 1982 | 218 | 0.010 |
Why?
|
| Chromatography, DEAE-Cellulose | 1 | 1969 | 82 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1992 | 1744 | 0.010 |
Why?
|
| Endarterectomy, Carotid | 1 | 1995 | 564 | 0.010 |
Why?
|
| Ischemic Attack, Transient | 1 | 1995 | 901 | 0.010 |
Why?
|
| Species Specificity | 2 | 1970 | 2418 | 0.000 |
Why?
|
| Hemagglutination Tests | 1 | 1968 | 76 | 0.000 |
Why?
|
| Antigen-Antibody Reactions | 1 | 1968 | 346 | 0.000 |
Why?
|
| Cellulose | 1 | 1968 | 118 | 0.000 |
Why?
|
| Angiocardiography | 1 | 1987 | 153 | 0.000 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 1968 | 202 | 0.000 |
Why?
|
| Serum Albumin | 2 | 1986 | 674 | 0.000 |
Why?
|
| Mitochondria, Muscle | 1 | 1968 | 172 | 0.000 |
Why?
|
| Sulfates | 1 | 1968 | 379 | 0.000 |
Why?
|
| gamma-Globulins | 1 | 1966 | 123 | 0.000 |
Why?
|
| Oxidative Phosphorylation | 1 | 1968 | 495 | 0.000 |
Why?
|
| Antibody Formation | 1 | 1971 | 1400 | 0.000 |
Why?
|
| Thrombolytic Therapy | 1 | 1995 | 2108 | 0.000 |
Why?
|
| Phospholipases A2 | 1 | 1985 | 197 | 0.000 |
Why?
|
| Prealbumin | 1 | 1986 | 222 | 0.000 |
Why?
|
| Phospholipases A | 1 | 1985 | 204 | 0.000 |
Why?
|
| Carotid Artery Diseases | 1 | 1990 | 883 | 0.000 |
Why?
|
| Muscles | 1 | 1968 | 1581 | 0.000 |
Why?
|
| Angina Pectoris | 1 | 1987 | 969 | 0.000 |
Why?
|
| Immunoassay | 1 | 1966 | 746 | 0.000 |
Why?
|
| Thyroidectomy | 1 | 1968 | 902 | 0.000 |
Why?
|
| Feminization | 1 | 1962 | 18 | 0.000 |
Why?
|
| Deglutition Disorders | 1 | 1988 | 626 | 0.000 |
Why?
|
| Umbilical Cord | 2 | 1974 | 181 | 0.000 |
Why?
|
| Testicular Diseases | 1 | 1962 | 73 | 0.000 |
Why?
|
| Cross Reactions | 2 | 1976 | 818 | 0.000 |
Why?
|
| Private Practice | 1 | 1982 | 152 | 0.000 |
Why?
|
| Disorders of Sex Development | 1 | 1962 | 128 | 0.000 |
Why?
|
| Gonadotropins | 1 | 1962 | 241 | 0.000 |
Why?
|
| Hypersensitivity | 1 | 1969 | 1155 | 0.000 |
Why?
|
| Anticoagulants | 1 | 1995 | 4897 | 0.000 |
Why?
|
| Testis | 1 | 1962 | 794 | 0.000 |
Why?
|
| Electrophoresis | 1 | 1978 | 234 | 0.000 |
Why?
|
| Metabolic Clearance Rate | 1 | 1979 | 361 | 0.000 |
Why?
|
| Uremia | 1 | 1979 | 201 | 0.000 |
Why?
|
| Psychotherapy | 1 | 1967 | 1640 | 0.000 |
Why?
|
| Chromatography, Affinity | 1 | 1978 | 534 | 0.000 |
Why?
|
| Drug Evaluation | 1 | 1978 | 641 | 0.000 |
Why?
|
| Haploidy | 1 | 1977 | 133 | 0.000 |
Why?
|
| Atrophy | 1 | 1962 | 1627 | 0.000 |
Why?
|
| Fatty Acids | 1 | 1985 | 1804 | 0.000 |
Why?
|
| Disease | 1 | 1962 | 671 | 0.000 |
Why?
|
| Cattle | 3 | 1972 | 3847 | 0.000 |
Why?
|
| Hormones | 1 | 1959 | 867 | 0.000 |
Why?
|
| Reflex, Stretch | 1 | 1974 | 23 | 0.000 |
Why?
|
| Chromatography, Thin Layer | 1 | 1973 | 212 | 0.000 |
Why?
|
| Mice | 2 | 1970 | 81208 | 0.000 |
Why?
|
| Fasting | 1 | 1978 | 1603 | 0.000 |
Why?
|
| Injections, Intravenous | 1 | 1974 | 1385 | 0.000 |
Why?
|
| Achilles Tendon | 1 | 1974 | 179 | 0.000 |
Why?
|
| Pituitary Gland | 1 | 1974 | 637 | 0.000 |
Why?
|
| Electroencephalography | 1 | 1967 | 6189 | 0.000 |
Why?
|
| Charcoal | 1 | 1971 | 64 | 0.000 |
Why?
|
| Guinea Pigs | 1 | 1972 | 1316 | 0.000 |
Why?
|
| Myxedema | 1 | 1969 | 18 | 0.000 |
Why?
|
| Sheep | 1 | 1972 | 1441 | 0.000 |
Why?
|
| Chromosome Disorders | 1 | 1972 | 499 | 0.000 |
Why?
|
| Autopsy | 1 | 1973 | 1007 | 0.000 |
Why?
|
| Neoplasm Metastasis | 1 | 1979 | 4902 | 0.000 |
Why?
|
| Dogs | 1 | 1972 | 3841 | 0.000 |
Why?
|
| Immunoglobulins | 1 | 1970 | 859 | 0.000 |
Why?
|
| Serum Albumin, Bovine | 1 | 1967 | 323 | 0.000 |
Why?
|
| Chromosome Aberrations | 1 | 1972 | 1764 | 0.000 |
Why?
|
| Cytoplasm | 1 | 1969 | 1516 | 0.000 |
Why?
|
| Ethanol | 1 | 1969 | 1323 | 0.000 |
Why?
|
| Thyroid Neoplasms | 1 | 1973 | 2332 | 0.000 |
Why?
|
| Adenocarcinoma | 1 | 1973 | 6315 | 0.000 |
Why?
|